Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|November 23, 2015
How to Optimize Management of Specialty Therapies
Author(s)Davy James, Managing Editor
Jon Hamrick, executive vice president, Biotech and Specialty Services at Therigy LLC, discusses techniques specialty pharmacies can use to improve workflow and clinical activities in therapy management.
Advertisement
Jon Hamrick, executive vice president, Biotech and Specialty Services at Therigy LLC, discusses techniques specialty pharmacies can use to improve workflow and clinical activities in therapy management.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
3
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
4
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
5